Bristol-Myers Squibb (BMY) stock slips despite earnings beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank
April 29, 2024 5:27 AM EDTDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
April 25, 2024 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of ($4.40), $0.07 better than the analyst estimate of ($4.47). Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
... More